3 news items
Why Ovid Therapeutics Shares Are Trading Lower By 19%? Here Are Other Stocks Moving In Monday's Mid-Day Session
AAN
AGRI
ALLG
17 Jun 24
cohort of its Phase 1/2 clinical trial of MB-106, showing an overall response rate of 90% with one patient remaining in complete remission at 31 months
Long-Term Data from Mirum's LIVMARLI Studies in ALGS and PFIC Highlighted at EASL Congress
MIRM
6 Jun 24
the durability of response to LIVMARLI across multiple clinical and laboratory outcomes. Data demonstrated that nearly all patients who remained on LIVMARLI
Mirum Pharmaceuticals' LIVMARLI Data Showcased at ESPGHAN Annual Meeting
MIRM
18 May 24
."
Abstract 587: Long-term Maintenance of Response and Improved Liver Health with Maralixibat in Patients
- Prev
- 1
- Next